Abstract

Prostaglandins (PGs) are naturally-occurring fatty acids synthesised from arachidonic acid by cyclo-oxygenase enzymes. Two PGs with circulatory actions, alprostadil (PGE₁; Prostin VR - Upjohn) and epoprostenol (prostacyclin, PGI₂; Flolan - Wellcome, Cyclo-Prostin - Upjohn) are marketed in Britain. Both have already found a place; alprostadil for neonates with congenital heart disease, epoprostenol for use in extracorporeal circulations and in patients with severe peripheral vascular disease.